Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra for CAR-T Toxicity in Large B-Cell Lymphoma
NCT04432506Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2020
- Primary completion
- May 2024
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anakinra in diffuse large B-cell lymphoma (DLBCL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of Any Grade Cytokine Release Syndrome at 30 days. Started Jul 2020; status: completed.
02
Drugs
anakinra
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04432506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04432506.